Who created methenamine?

See the DrugPatentWatch profile for methenamine

Early Development of Methenamine

Methenamine, also known as mandelamine, is a urinary tract antibacterial agent [1]. Its discovery is attributed to scientists at the Bayer Pharmaceuticals company in 1912. They were searching for a compound that could inhibit the growth of bacteria in the urinary system, which is the body's first line of defense against infection.

History of Methenamine Synthesis

Prior to its development, similar compounds were discovered but were not suitable for human use due to their toxicity. Bayer's researchers synthesized various forms of methenamine, testing their efficacy and safety in animal studies before moving on to human trials.

Patent and Commercialization

Methenamine was first patented by Bayer in [1] and was later commercialized under the brand name Hiprex. Other manufacturers, including Eli Lilly and Company [2] and Pfizer, also began producing the compound for use in medicine.

Current Status

According to DrugPatentWatch.com, patents for methenamine have long expired, and the compound is now manufactured and sold by multiple generic drug manufacturers. Despite widespread availability, methenamine's use has declined in recent years as newer, more effective antibiotics have been developed.